Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer.

Description

This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.

Conditions

Colo-rectal Cancer, Colorectal Cancer Recurrent

Talk to us

Study Overview

On this page

Study Details

Study overview

This study aims to establish an exosome-based liquid biopsy signature to detect molecular residual disease (MRD) in stage II-III colorectal cancer (CRC) patients. Identifying patients with MRD after surgery is crucial for selecting appropriate candidates for adjuvant chemotherapy (ACT), allowing for more personalized treatment approaches and potentially improving patient outcomes.

An Exosome-Based Liquid Biopsy Assay to Detect Molecular Residual Disease for the Identification of High-Risk Patients with Stage II-III Colorectal Cancer

Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer.

Condition
Colo-rectal Cancer
Intervention / Treatment

-

Contacts and Locations

Duarte

City of Hope Medical Center, Duarte, California, United States, 91010

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Patients with pathologically confirmed stage II or III colorectal cancer.
  • 2. Patients who have undergone curative-intent surgery.
  • 3. Patients with no evidence of distant metastasis (stage IV).
  • 4. Patients aged 18 years or older.
  • 5. Patients who provided written informed consent.
  • 1. Patients with stage IV cancer or those receiving neoadjuvant therapy.
  • 2. Patients with non-curative resection or requiring urgent surgery.
  • 3. Patients with a follow-up period of fewer than 3 years.
  • 4. Patients with severe comorbidities or who are unable to participate in follow-up assessments.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

City of Hope Medical Center,

Ajay Goel, PhD, PRINCIPAL_INVESTIGATOR, City of Hope Medical Center

Study Record Dates

2024-12-30